d1banner.jpg d1bannerph.jpg

About Sinopep

Driving Innovations in Pharmaceuticals

At Sinopep, we are driven to be the trailblazers, advancing peptides, oligonucleotides, and small molecules as lifesaving therapeutic solutions, establishing our leadership in research, development, and manufacturing in pharmaceutical industry. Our unwavering dedication to innovation, pursuit of excellence in execution, and continuous expansion of manufacturing capacities put us in the leading position amongst our peers and competitors.

  • Mission

    Driven to save lives and improve human health through innovations.

  • Vision

    We strive to be an industry leader and a trusted global partner in drug development to improve quality of life.

  • Core Values

    · Integrity & Accountability
    · Technology driven, Customer conscious, Urgency
    · Open minded, collaborative, and Inclusive

Innovative Solutions for Seamless Collaboration

With our strong commitment to innovation and technology driven mindset, we have established a comprehensive API and drug product supply chain solution enabling our global partners to bring both innovative breakthroughs and cost saving alternatives to patients at any point of the clinical development and commercial stages, in a collaborative and social responsible manner.

  • 15years
    Of experience
  • 12,500sqm
    State-of-the-art facility
  • 1,700+
  • BD Representatives
  • Manufacturing Sites
  • R&D Centers
  • Hangzhou Yuhang R&D
  • Hangzhou Xiasha R&D
  • Lianyungang R&D
  • Zhejiang Jiande
  • Jiangsu Lianyungang
  • Boston, USA
  • Paris, France


  • 2022

    Apextide for oligos founded.

  • 2021

    IPO in Shanghai Stock Exchange.

  • 2019

    3rd  FDA inspection of Sinopep plant.

  • 2017

    Merged as Sinopep-Allsino Biopharmaceuticals.

  • 2016

    2nd  FDA inspection of  Sinopep plant.

  • 2014

    1st  FDA inspection of Sinopep plant.

  • 2009

    Sinopep Pharm founded.